PBK/TOPK Is a Novel Mitotic Kinase Which Is Upregulated in Burkitt's Lymphoma and Other Highly Proliferative Malignant Cells
- 1 September 2001
- journal article
- Published by Elsevier BV in Blood Cells, Molecules, and Diseases
- Vol. 27 (5), 825-829
- https://doi.org/10.1006/bcmd.2001.0452
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Flavopiridol Induces Apoptosis and Caspase-3 Activation of a Newly Characterized Burkitt's Lymphoma Cell Line Containing Mutant P53 GenesBlood Cells, Molecules, and Diseases, 2001
- A high bone marrow plasma cell labeling index in stable plateau–phase multiple myeloma is a marker for early disease progression and deathBlood, 2001
- Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current statusExpert Opinion on Investigational Drugs, 2000
- Cloning and Expression of a Novel MAPKK-like Protein Kinase, Lymphokine-activated Killer T-cell-originated Protein Kinase, Specifically Expressed in the Testis and Activated Lymphoid CellsJournal of Biological Chemistry, 2000
- Characterization of PDZ-binding kinase, a mitotic kinaseProceedings of the National Academy of Sciences, 2000
- Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1British Journal of Haematology, 1999
- Prognostic Value of Lymphoma-specific S-Phase Fraction Compared with that of Other Cell Proliferation MarkersActa Oncologica, 1999
- Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.Journal of Clinical Oncology, 1998
- Value of beta 2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myelomaBlood, 1988